Sarcoma / 2015 / Article / Tab 1

Research Article

Phase II Trial of Gemcitabine and Docetaxel with Bevacizumab in Soft Tissue Sarcoma

Table 1

Patient characteristics.

CharacteristicAll patientsGDB patients

Total4435

Male22 (50%)15 (43%)
Female22 (50%)20 (57%)
Age
 Median54.554
 Range24–7539–72
ECOG
 Median00
 Range0-10-1
Tumor type
 Leiomyosarcoma20 (45%)18 (51%)
  Uterine55
  Nonuterine1513
 Undifferentiated pleomorphic sarcoma17 (39%)11 (31%)
 Angiosarcoma (liver, bone, soft tissue)6 (14%)5 (14%)
 Pleomorphic liposarcoma1 (2%)1 (3%)
Prior treatment
 Doxorubicin (or liposomal doxorubicin)85
 Ifosfamide53
 Dacarbazine32
 Sorafenib21
 None34 (77%)29 (83%)

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.